AGMBNasdaq
AgomAb Therapeutics NV
Healthcare·Immunology·Phase 2·Antwerp, Belgium
ImmunologyRespiratory
AgomAb Therapeutics NV (AGMB): 3 clinical trials. Updated within the last hour.
Key Financials
Market Cap
$515.1M
Cash
—
Quarterly Burn
—
Runway
—
Revenue
—
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
26
Total value held
$138.2M
| Holder | Shares | Value |
|---|---|---|
| eqt fund management s.a r.l. | 5,141,992 | $53.9M |
| federated hermes, inc. | 1,618,000 | $17.0M |
| andera partners | 1,538,702 | $16.1M |
| fmr llc | 1,458,677 | $15.3M |
| perceptive advisors llc | 1,200,000 | $12.6M |
| samsara biocapital, llc | 600,000 | $6.3M |
| siren, l.l.c. | 411,250 | $4.3M |
| lmr partners llp | 300,000 | $3.1M |
| seven grand managers, llc | 200,000 | $2.1M |
| redmile group, llc | 156,250 | $1.6M |
Showing top 10 of 26 institutional holders of AgomAb Therapeutics NV. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
3 clinical trials·CEO: Dr. Tim Knotnerus MSc, Ph.D.
Frequently asked questions
What is AgomAb Therapeutics NV's market capitalization?
AgomAb Therapeutics NV's market capitalization is approximately $515.1M.
Who is the CEO of AgomAb Therapeutics NV?
Dr. Tim Knotnerus MSc, Ph.D. is the chief executive officer of AgomAb Therapeutics NV (AGMB).
Get the full picture on AgomAb Therapeutics NV
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.